Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cubist, Teva settle litigation surrounding Cubicin

Executive Summary

Cubist Pharmaceuticals Inc. (therapies for the acute care market) and Teva Pharmaceutical Industries Ltd. have settled patent litigation surrounding the former’s antibiotic Cubicin (daptomycin). In early 2009, Cubist claimed Teva infringed on patents by filing for FDA approval of a generic version of the drug. Under terms of the settlement, Cubist licensed Teva non-exclusive rights to sell daptomycin in the US as of either December 24, 2017 or, if Cubist obtains a six-month extension of pediatric marketing exclusivity, then June 24, 2018. Teva will exclusively purchase its daptomycin requirements from Cubist based on both the cost of goods sold plus a margin and a specified percentage of net profits from sales of generic daptomycin.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register